Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16483378 | 0.92 | GPR119 (0.48) | GPR119DDB1CRBNHPGDUSP2 | |
| SCHEMBL27123310 | 0.88 | GPR119 (0.54) | GPR119DDB1CRBNHPGDUSP2 | |
| SCHEMBL30864050 | 0.88 | GPR119 (0.51) | GPR119DDB1CRBNHPGDUSP2 | |
| SCHEMBL30864086 | 0.86 | GPR119 (0.57) | GPR119DDB1CRBNHPGD | |
| SCHEMBL416508 | 0.86 | HPGD (0.51) | GPR119HPGDUSP2SMN1; SMN2RECQL | |
| SCHEMBL1224898 | 0.85 | GPR119 (0.54) | GPR119 | |
| SCHEMBL30984923 | 0.85 | GPR119 (0.56) | GPR119DDB1CRBNHPGDUSP2 | |
| SCHEMBL24693734 | 0.83 | GPR119 (0.55) | GPR119DDB1CRBNHPGDUSP2 | |
| SCHEMBL17104452 | 0.83 | GPR119 (0.57) | GPR119DDB1CRBNHPGDUSP2 | |
| SCHEMBL16466417 | 0.83 | GPR119 (0.52) | GPR119DDB1CRBNHPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631942-A1 | PAN-KRAS DEGRADING AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| EP-4606803-A1 | KRAS G12D DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| CN-119948027-A | SOS1 protein degradation agent and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-115232108-B | SOS1 degradation agent and preparation method and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| WO-2024146502-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-07-11 | — | — | WO | disclosed |
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024083258-A1 | KRAS G12C DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | 上海领泰生物医药科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| WO-2022223039-A1 | SOS1 DEGRADER, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223033-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| CN-115232108-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232114-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232111-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-2906542-B1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9708270-B2 | Substituted spiropiperidinyl compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2906542-A2 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014059232-A2 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SOS1, RAC1, RSU1 | GPR119 3494/4885DDB1 1803/4885CRBN 802/4885 |
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | GPR119 2690/4885DDB1 2931/4885CRBN 545/4885 |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RAC1, SOS1, RSU1 | GPR119 3124/4885DDB1 1921/4885CRBN 606/4885 |
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR180, GPR88 | GPR119 1/4885DDB1 4529/4885CRBN 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.